在最新电话会议中,West Pharmaceutical高管明确表示,公司对2026年GLP-1类药物市场前景保持乐观。无论是注射剂型还是口服剂型,均被预期为驱动业务增长的双引擎。这一表态凸显了企业对该细分领域长期需求的信心,同时也反映出制药行业技术路线多元化的趋势正在加速渗透。
在最新电话会议中,West Pharmaceutical高管明确表示,公司对2026年GLP-1类药物市场前景保持乐观。无论是注射剂型还是口服剂型,均被预期为驱动业务增长的双引擎。这一表态凸显了企业对该细分领域长期需求的信心,同时也反映出制药行业技术路线多元化的趋势正在加速渗透。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.